Ernexa Therapeutics Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Ernexa Therapeutics Inc. (ERNA) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $320.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- Ernexa Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $320.00K, a 13.28% decline year-over-year.
- Ernexa Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $309.00K, a 38.45% decline year-over-year.
- Ernexa Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $333.00K, a 18.78% decline year-over-year.
- Ernexa Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $293.00K, a 27.65% decline year-over-year.
- Ernexa Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $1.50M, a 1.58% decline from fiscal 2024.
- Ernexa Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $1.52M, a 22.38% increase from fiscal 2023.
- Ernexa Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $1.24M, a 57.68% decline from fiscal 2022.
- Ernexa Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $2.94M, a 43.94% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $320.00K 10-Q · filed 2026-08-06 | $629.00K 10-Q · filed 2026-08-06 | $962.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.25M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $309.00K 10-Q · filed 2026-05-11 | $642.00K derived: sum of 2 quarters · filed 2026-05-11 | $935.00K derived: sum of 3 quarters · filed 2026-05-11 | $1.30M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $333.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $626.00K derived: sum of 2 quarters · filed 2026-03-13 | $995.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.50M 10-K · filed 2026-03-13 | ||||
| 2025-09-30 | $293.00K 10-Q · filed 2025-11-07 | $662.00K derived: sum of 2 quarters · filed 2026-08-06 | $1.16M 10-Q · filed 2025-11-07 | $1.57M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $369.00K 10-Q · filed 2026-08-06 | $368.00K 10-Q · filed 2025-08-13 | $870.00K 10-Q · filed 2026-08-06 | $1.28M derived: sum of 3 quarters · filed 2026-08-06 | $1.69M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-03-31 | $502.00K 10-Q · filed 2026-05-11 | $912.00K derived: sum of 2 quarters · filed 2026-05-11 | $1.32M derived: sum of 3 quarters · filed 2026-05-11 | $1.74M derived: sum of 4 quarters · filed 2026-05-11 | ||||
| 2024-12-31 | $410.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $815.00K derived: sum of 2 quarters · filed 2026-03-13 | $1.24M derived: sum of 3 quarters · filed 2026-03-13 | $1.52M 10-K · filed 2026-03-13 | ||||
| 2024-09-30 | $405.00K 10-Q · filed 2025-11-07 | $828.00K derived: sum of 2 quarters · filed 2025-11-07 | $1.11M 10-Q · filed 2025-11-07 | $1.27M derived: sum of 4 quarters · filed 2025-11-07 | ||||
| 2024-06-30 | $423.00K 10-Q · filed 2025-08-13 | $705.00K 10-Q · filed 2025-08-13 | $870.00K derived: sum of 3 quarters · filed 2025-08-13 | $1.04M derived: sum of 4 quarters · filed 2025-08-13 | ||||
| 2024-03-31 | $282.00K 10-Q · filed 2025-05-07 | $447.00K derived: sum of 2 quarters · filed 2025-05-07 | $621.00K derived: sum of 3 quarters · filed 2025-05-07 | $835.00K derived: sum of 4 quarters · filed 2025-05-07 | ||||
| 2023-12-31 | $165.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $339.00K derived: sum of 2 quarters · filed 2025-03-12 | $553.00K derived: sum of 3 quarters · filed 2025-03-12 | $1.24M 10-K · filed 2025-03-12 | ||||
| 2023-09-30 | $174.00K 10-Q · filed 2024-11-12 | $388.00K derived: sum of 2 quarters · filed 2024-11-12 | $1.08M 10-Q · filed 2024-11-12 | $1.47M derived: sum of 4 quarters · filed 2024-11-12 | ||||
| 2023-06-30 | $214.00K 10-Q · filed 2024-08-13 | $903.00K 10-Q · filed 2024-08-13 | $1.30M derived: sum of 3 quarters · filed 2024-08-13 | $1.77M derived: sum of 4 quarters · filed 2024-08-13 | ||||
| 2023-03-31 | $689.00K 10-Q · filed 2024-05-14 | $1.08M derived: sum of 2 quarters · filed 2024-05-14 | $1.56M derived: sum of 3 quarters · filed 2024-05-14 | $2.44M derived: sum of 4 quarters · filed 2024-05-14 | ||||
| 2022-12-31 | $396.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $872.00K derived: sum of 2 quarters · filed 2024-03-14 | $1.75M derived: sum of 3 quarters · filed 2024-03-14 | $2.94M 10-K · filed 2024-03-14 | ||||
| 2022-09-30 | $476.00K 10-Q · filed 2023-11-13 | $1.35M derived: sum of 2 quarters · filed 2023-11-13 | $2.54M 10-Q · filed 2023-11-13 | $2.54M 10-Q · filed 2022-11-14 | $4.47M derived: sum of 4 quarters · filed 2023-11-13 | |||
| 2022-06-30 | $879.00K 10-Q · filed 2023-08-11 | $2.06M 10-Q · filed 2023-08-11 | $4.00M derived: sum of 3 quarters · filed 2023-08-11 | $5.72M derived: sum of 4 quarters · filed 2023-08-11 | ||||
| 2022-03-31 | $1.18M 10-Q · filed 2023-05-11 | $3.12M derived: sum of 2 quarters · filed 2023-05-11 | $4.84M derived: sum of 3 quarters · filed 2023-05-11 | $6.00M derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | $1.93M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $3.66M derived: sum of 2 quarters · filed 2023-03-20 | $4.82M derived: sum of 3 quarters · filed 2023-03-20 | $5.24M 10-K · filed 2023-03-20 | ||||
| 2021-09-30 | $1.73M 10-Q · filed 2022-11-14 | $1.73M 10-Q · filed 2021-11-12 | $2.88M derived: sum of 2 quarters · filed 2022-11-14 | $3.30M 10-Q · filed 2022-11-14 | $3.30M 10-Q · filed 2021-11-12 | $3.32M derived: sum of 4 quarters · filed 2022-11-14 | ||
| 2021-06-30 | $1.15M 10-Q · filed 2022-08-11 | $1.15M 10-Q · filed 2021-08-13 | $1.57M 10-Q · filed 2022-08-11 | $1.57M 10-Q · filed 2021-08-13 | $1.60M derived: sum of 3 quarters · filed 2022-08-11 | $1.62M derived: sum of 4 quarters · filed 2022-08-11 | ||
| 2021-03-31 | $419.00K 10-Q · filed 2022-07-01 | $441.80K derived: sum of 2 quarters · filed 2022-07-01 | $464.53K derived: sum of 3 quarters · filed 2022-07-01 | $487.27K derived: sum of 4 quarters · filed 2022-07-01 | ||||
| 2020-12-31 | $22.80K derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-07-01 | $45.53K derived: sum of 2 quarters · filed 2022-07-01 | $68.27K derived: sum of 3 quarters · filed 2022-07-01 | $91.00K 10-K/A · filed 2022-07-01 | $199.00K 10-K · filed 2021-03-11 | |||
| 2020-09-30 | $22.73K 10-Q · filed 2021-11-12 | $53.00K 10-Q · filed 2020-11-13 | $45.47K derived: sum of 2 quarters · filed 2021-11-12 | $68.20K 10-Q · filed 2021-11-12 | $135.00K 10-Q · filed 2020-11-13 | $118.47K derived: sum of 4 quarters · filed 2021-11-12 | ||
| 2020-06-30 | $22.73K 10-Q · filed 2021-08-13 | $43.00K 10-Q · filed 2020-08-07 | $45.47K 10-Q · filed 2021-08-13 | $82.00K 10-Q · filed 2020-08-07 | $95.73K derived: sum of 3 quarters · filed 2021-08-13 | $158.73K derived: sum of 4 quarters · filed 2021-08-13 | ||
| 2020-03-31 | $39.00K 10-Q · filed 2020-05-20 | $73.00K derived: sum of 2 quarters · filed 2021-03-11 | $136.00K derived: sum of 3 quarters · filed 2021-03-11 | $186.00K derived: sum of 4 quarters · filed 2021-03-11 | ||||
| 2019-12-31 | $34.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $97.00K derived: sum of 2 quarters · filed 2021-03-11 | $147.00K derived: sum of 3 quarters · filed 2021-03-11 | $206.00K 10-K · filed 2021-03-11 | ||||
| 2019-09-30 | $63.00K 10-Q · filed 2020-11-13 | $113.00K derived: sum of 2 quarters · filed 2020-11-13 | $172.00K 10-Q · filed 2020-11-13 | $247.00K derived: sum of 4 quarters · filed 2020-11-13 | ||||
| 2019-06-30 | $50.00K 10-Q · filed 2020-08-07 | $109.00K 10-Q · filed 2020-08-07 | $184.00K derived: sum of 3 quarters · filed 2020-08-07 | $301.00K derived: sum of 4 quarters · filed 2020-08-07 | ||||
| 2019-03-31 | $59.00K 10-Q · filed 2020-05-20 | $134.00K derived: sum of 2 quarters · filed 2020-05-20 | $251.00K derived: sum of 3 quarters · filed 2020-05-20 | $385.00K derived: sum of 4 quarters · filed 2020-05-20 | ||||
| 2018-12-31 | $75.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-19 | $192.00K derived: sum of 2 quarters · filed 2020-03-19 | $326.00K derived: sum of 3 quarters · filed 2020-03-19 | $443.00K 10-K · filed 2020-03-19 | ||||
| 2018-09-30 | $117.00K 10-Q · filed 2019-11-01 | $251.00K derived: sum of 2 quarters · filed 2019-11-01 | $368.00K 10-Q · filed 2019-11-01 | |||||
| 2018-06-30 | $134.00K 10-Q · filed 2019-08-12 | $251.00K 10-Q · filed 2019-08-12 | ||||||
| 2018-03-31 | $117.00K 10-Q · filed 2019-05-14 | |||||||
| 2017-12-31 | $457.00K 10-K · filed 2019-03-22 | |||||||
| 2016-12-31 | $419.00K 10-K · filed 2018-03-09 | |||||||
| 2015-12-31 | $456.00K 10-K · filed 2017-03-09 | |||||||
| 2014-12-31 | $282.00K 10-K · filed 2016-03-15 | |||||||
| 2013-12-31 | $132.00K 10-K · filed 2015-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |